User menu

Iodide organification disorder in autonomous thyroid nodule

Bibliographic reference Tang, B. ; Daumerie, Chantal ; Corvilain, B. ; Seret, A. ; Moreno-Reyes, R.. Iodide organification disorder in autonomous thyroid nodule.13th International Thyroid Congress (Buenos Aires (AR), du 30/10/2005 au 04/11/2005). In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 33, no. 2, p. S351-S351 (2006)
Permanent URL
  1. Kuratsu J, Takeshima H, Ushio Y. Trends in the incidence of primary intracranial tumors in Kumamoto, Japan. Int J Clin Oncol 2001;6:183–91
  2. Ferrari G, Lovaste MG, Moresco M, Rossi G. Primary intracranial tumors. Survey of incidence in the province of Trento in the years 1977–1981. Ital J Neurol Sci 1985;6:191–6
  3. Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000;85:4596–602
  4. Swearingen B, Barker FG II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419–26
  5. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 2002;87:3180–6
  6. Mampalam Thomas J., Transsphenoidal Microsurgery for Cushing Disease : A Report of 216 Cases, 10.7326/0003-4819-109-6-487
  7. Davis PC, Hoffman JC Jr, Tindall GT, Braun IF. CT-surgical correlation in pituitary adenomas: evaluation in 113 patients. Am J Neuroradiol 1985;6:711–6
  8. Nakane T, Kuwayama A, Watanabe M, Takahashi T, Kato T, Ichihara K, et al. Long term results of transsphenoidal adenomectomy in patients with Cushing’s disease. Neurosurgery 1987;21:218–22
  9. Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996;81:3084–90
  10. Sano T, Yamada S. Histologic and immunohistochemical study of clinically non-functioning pituitary adenomas: special reference to gonadotropin-positive adenomas. Pathol Int 1994;44:697–703
  11. Sheehan JP, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for residual or recurrent nonfunctioning pituitary adenoma. J Neurosurg 2002;97:408–14
  12. Shin M. Gamma knife radiosurgery for pituitary adenoma. Biomed Pharmacother 2002;56 Suppl 1:178s–81s
  13. Kremer P, Forsting M, Hamer J, Sartor K. MR imaging of residual tumor tissue after transsphenoidal surgery of hormone-inactive pituitary macroadenomas: a prospective study. Acta Neurochir Suppl 1996;65:27–30
  14. Kremer P, Forsting M, Ranaei G, Wuster C, Hamer J, Sartor K, et al. Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma. Acta Neurochir (Wien) 2002;144:433–43
  15. Rodriguez O, Mateos B, de la Pedraja R, Villoria R, Hernando JI, Pastor A, et al. Postoperative follow-up of pituitary adenomas after trans-sphenoidal resection: MRI and clinical correlation. Neuroradiology 1996;38:747–54
  16. Steiner E, Knosp E, Herold C J, Kramer J, Stiglbauer R, Staniszewski K, Imhof H, Pituitary adenomas: findings of postoperative MR imaging., 10.1148/radiology.185.2.1410366
  17. Kaiser W., Steckelbroeck V., Siewert B., Layer G., Hochstetter A., Reiser M., Differenzierung zwischen Tumor und Implantatmaterial in der postoperativen Sella mit der MRT, 10.1055/s-2008-1032700
  18. Battistin L, Gerstenbrand F. PET and NMR: new perspectives in neuroimaging and in clinical neurochemistry. New York: Liss; 1986. p. 407–24
  19. Bergstrom M, Muhr C, Lundberg PO, Langstrom B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 1991;32:610–5
  20. Comar D, Cartron J, Maziere M, Marazano C. Labelling and metabolism of methionine-methyl-11C. Eur J Nucl Med 1976;1:11–4
  21. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997;38:1459–62
  22. Sakamoto Y, Takahashi M, Korogi Y, Bussaka H, Ushio Y, Normal and abnormal pituitary glands: gadopentetate dimeglumine-enhanced MR imaging., 10.1148/radiology.178.2.1987606
  23. Peck WW, Dillon WP, Norman D, Newton TH, Wilson CB, High-resolution MR imaging of pituitary microadenomas at 1.5 T: experience with Cushing disease, 10.2214/ajr.152.1.145
  24. Cano A, Martinez M, Benito P, Tofe S, Higuera A, Munoz R. Analysis of indirect signs of microprolactinoma at MR imaging. Eur J Radiol 1999;31:157–64
  25. Levivier M. Integration of metabolic data by positron emission tomography in image-guided neurosurgical interventions [in French]. Bull Mem Acad R Med Belg 2002;157:235–45; discussion 245–50
  26. Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D, et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 2004;45:1146–54
  27. Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S, et al. Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 2005;71:161–8
  28. Yoon PH, Kim DI, Jeon P, Lee SI, Lee SK, Kim SH. Pituitary adenomas: early postoperative MR imaging after transsphenoidal resection. Am J Neuroradiol 2001;22:1097–104
  29. Rajaraman V, Schulder M. Postoperative MRI appearance after transsphenoidal pituitary tumor resection. Surg Neurol 1999;52:592–8; discussion 598–9
  30. Bergstrom M, Muhr C, Lundberg PO, Bergstrom K, Gee AD, Fasth KJ, et al. Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study. J Comput Assist Tomogr 1987;11:815–9
  31. Muhr Carin, Bergström M., Positron emission tomography applied in the study of pituitary adenomas, 10.1007/bf03346855
  32. Scippo ML, Beckers A, Frankenne F, Reznik M, Stevenaert A, Igout A, et al. Adenohypophysis hormone gene products in 14 pituitary adenomas: analysis by immunohistochemistry and northern blotting. Arch Int Physiol Biochim Biophys 1991;99:135–40
  33. Jameson JL, Klibanski A, Black PM, Zervas NT, Lindell CM, Hsu DW, et al. Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas. J Clin Invest 1987;80:1472–8
  34. Yeh PJ, Chen JW. Pituitary tumors: surgical and medical management. Surg Oncol 1997;6:67–92
  35. Buchfelder M, Nistor R, Fahlbusch R, Huk WJ. The accuracy of CT and MR evaluation of the sella turcica for detection of adrenocorticotropic hormone-secreting adenomas in Cushing disease. Am J Neuroradiol 1993;14:1183–90
  36. Levivier M, Goldman S, Bidaut LM, Luxen A, Stanus E, Przedborski S, et al. Positron emission tomography-guided stereotactic brain biopsy. Neurosurgery 1992;31:792–7; discussion 797
  37. Levivier M, Goldman S, Pirotte B, Brucher JM, Baleriaux D, Luxen A, et al. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. J Neurosurg 1995;82:445–52
  38. Levivier M, Wikier D, Goldman S, David P, Metens T, Massager N, et al. Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: early experience with brain tumors. Technical note. J Neurosurg 2000;93 Suppl 3:233–8
  39. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 1996;78:1098–106
  40. Brada M, Ajithkumar TV, Minniti G. Radiosurgery for pituitary adenomas. Clin Endocrinol (Oxf) 2004;61:531–43
  41. De Souza B, Brunetti A, Fulham M J, Brooks R A, DeMichele D, Cook P, Nieman L, Doppman J L, Oldfield E H, Di Chiro G, Pituitary microadenomas: a PET study., 10.1148/radiology.177.1.2399336
  42. Hanakawa K, Ikeda H, Ishii K, Asamoto S, Iwata T, Matsumoto K, et al. High uptake on 11C methionine PET scan in the pituitary gland of a patient with cerebral glioma after surgical abortion [in Japanese]. No To Shinkei 1998;50:573–7
  43. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148–55
  44. Colao A., Lastoria S., Lombardi G., Kwekkeboom D. J., de Herder W. W., Krenning E. P., Receptor imaging in the diagnosis and treatment of pituitary tumors, 10.1007/bf03343636
  45. Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, et al. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas. Q J Nucl Med 1995;39:90–3
  46. Koga M, Nakao H, Arao M, Sato B, Noma K, Morimoto Y, et al. Demonstration of specific dopamine receptors on human pituitary adenomas. Acta Endocrinol (Copenh) 1987;114:595–602